aleniglipron
AssetAlso GSBR-1290
Activates GLP-1 receptors to reduce appetite and promote weight loss.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Insulin/IGF-1 signalling
- 5
- Indications
- 2
- Trials
- 2
- Developers
Indications
5Obesity
Phase 2, doi.org, 5 Jun 2026
Obesity, overweight, or chronic weight management
Phase 2, Completed, NCT07169942, clinicaltrials.gov, 17 Oct 2026
Overweight
Phase 2, doi.org, 5 Jun 2026
2 more
In the full profile
- Targets and what it contains2
- Owner and partners2
- Trials2
- Evidence for its targets3
- Competitors12
- Signals5
Every asset’s record: target, stage, trials and the evidence behind it.